International Journal of Drug Delivery Technology
Volume 15, Issue 2

Synthesis of Chitosan Based Nanocomposite with 3-(2-(3,4-dimethoxyphenyl)-2-oxoethylidene) indolin-2-one (RAJI) for Efficient Therapy Against Triple Negative Breast Cancer 

Sivaprakasam P, Purushothaman D, Pandurangan A K* 

School of Life Sciences, B. S. Abdur Rahman Crescent Institute of Science and Technology, Vandalur, Chennai, India

Received: 18th Apr, 2025; Revised: 11th May, 2025; Accepted: 28th May, 2025; Available Online: 25th Jun, 2025 

ABSTRACT

Cancer is defined by the unregulated and excessive growth of abnormal cells, eventually leading to the destruction of body tissues. Among various cancer types, breast cancer is notably prevalent in females generally originating in the ducts or lobules forming lumps or tumours and subsequently metastasizing to other regions of the body. The treatment of breast cancer is contingent upon its stage and typically involves surgery, chemotherapy, radiation, hormone therapy, etc. Drugs currently available on the market frequently induce substantial adverse effects, which has prompted the development of innovative therapeutic agents. In this study, we propose the use of a novel compound, 3-(2-(3,4-dimethoxyphenyl)-2-oxoethylidene) indolin-2-one (RAJI), with chitosan to create a nanocomposite for the purpose of developing an effective breast cancer treatment. RAJI-loaded chitosan nanocomposite was synthesized using a high-pressure homogenizer and subsequently characterized to assess their physicochemical properties and drug loading profile. The In-vitro toxicity analyses of RAJI on MDA-MB-231 cells - a Triple Negative Breast Cancer (TNBC) cell line, demonstrated its potent anti-cancer properties. Consequently, we speculate that the efficaciousness of RAJI-loaded chitosan nanocomposite in the treatment of TNBC will be superior to that of other commercially available medicines.

Keywords: Breast cancer, Triple Negative Breast Cancer, Drug, RAJI, Chitosan, Nanocomposite.

How to cite this article: Sivaprakasam P, Purushothaman D, Pandurangan A K. Synthesis of Chitosan Based Nanocomposite with 3-(2-(3,4-dimethoxyphenyl)-2-oxoethylidene) indolin-2-one (RAJI) for Efficient Therapy Against Triple Negative Breast Cancer. International Journal of Drug Delivery Technology. 2025;15(2):656-63. doi: 10.25258/ijddt.15.2.36

REFERENCE

  1. Cui YY. Cancer, Mankind’s Challenge. Curr Cancer Reports. 2019;1:1–5.
  2. Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the definition of cancer. Mol Cancer Res. 2023;21(11):1142–7.
  3. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(07):783–91.
  4. Mir MA, Qayoom H. Introduction to breast cancer. In: Therapeutic potential of cell cycle kinases in breast cancer. Springer; 2023. p. 1–22.
  5. Shaikh K, Krishnan S, Thanki R, Shaikh K, Krishnan S, Thanki R. An introduction to breast cancer. Artif Intell breast cancer early Detect diagnosis. 2021;1–20.
  6. Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, et al. Cancer statistics, 2020: report from national cancer registry programme, India. JCO Glob Oncol. 2020;6:1063–75.
  7. Sinn HP, Varga Z. Triple-negatives Mammakarzinom. Die Pathol. 2023;44(1):32–8.
  8. Novoa SA, Rodríguez CA, Cruz J, López-Tarruella S, Tibau A, Adrover E, et al. Abstract P4-07-45: Treatment strategies for advanced triple negative breast cancer patients as per routine clinical practice: analysis from the observational study GEICAM/2014-03 (RegistEM). Cancer Res. 2023;83(5_Supplement):P4-07.
  9. Naik J, Kuchekar B, Kuchekar A, Pujari R. Novel treatment strategies for Triple-negative breast cancers: A comprehensive review. Hacettepe Univ J Fac Pharm. 2023;43(2):174–84.
  10. Sivaprakasam P, Chandrabose K, Pandurangan AK. In-vivo Toxicity Evaluation of 3-(2-(3,4 dimethoxyphenyl)-2 oxoethylidene) Indolin-2-one (RAJI) in Zebrafish and Mice Model. Asian Pac J Cancer Prev. 2024;25(9):3159–72.
  11. Prathibha Sivaprakasam, Karthikeyan Chandrabose, Suresh Kumar Anandasadagopan AKP. Evaluating the Cytotoxic Potential of 3-(2-(3,4 dimethoxyphenyl)-2-oxoethylidene) indolin-2- one) (RAJI) on Triple Negative Breast Cancer Cells. Asian Pacific J Cancer Prev APJCP [Internet]. 2025; Available from: http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=29693347&site=eds-live
  12. Rizeq BR, Younes NN, Rasool K, Nasrallah GK. Synthesis, bioapplications, and toxicity evaluation of chitosan-based nanoparticles. Int J Mol Sci. 2019;20(22):5776.
  13. Ahmad M, Manzoor K, Ahmad S, Akram N, Ikram S. Chitosan-based nanocomposites for cardiac, liver, and wound healing applications. In: Applications of nanocomposite materials in orthopedics. Elsevier; 2019. p. 253–62.
  14. Jhaveri J, Raichura Z, Khan T, Momin M, Omri A. Chitosan nanoparticles-insight into properties, functionalization and applications in drug delivery and theranostics. Molecules. 2021;26(2):272.
  15. Rostami E. Progresses in targeted drug delivery systems using chitosan nanoparticles in cancer therapy: A mini-review. J Drug Deliv Sci Technol. 2020;58:101813.
  16. Wu YX, Ma H, Wang JL, Qu W. Production of chitosan scaffolds by lyophilization or electrospinning: which is better for peripheral nerve regeneration? Neural Regen Res. 2021;16(6):1093–8.
  17. Torres-Rivero K, Bastos-Arrieta J, Fiol N, Florido A. Metal and metal oxide nanoparticles: an integrated perspective of the green synthesis methods by natural products and waste valorization: applications and challenges. Compr Anal Chem. 2021;94:433–69.
  18. Al-Qubaisi MS, Al-Abboodi AS, Alhassan FH, Hussein-Al-Ali S, Flaifel MH, Eid EEM, et al. Preparation, characterization, in vitro drug release and anti-inflammatory of thymoquinone-loaded chitosan nanocomposite. Saudi Pharm J. 2022;30(4):347–58.
  19. Nga NTH, Ngoc TTB, Trinh NTM, Thuoc TL, Thao DTP. Optimization and application of MTT assay in determining density of suspension cells. Anal Biochem. 2020;610:113937.
  20. Wang G, Li R, Parseh B, Du G. Prospects and challenges of anticancer agents’ delivery via chitosan-based drug carriers to combat breast cancer: A review. Carbohydr Polym. 2021;268:118192.
  21. Taherian A, Esfandiari N, Rouhani S. Breast cancer drug delivery by novel drug-loaded chitosan-coated magnetic nanoparticles. Cancer Nanotechnol. 2021;12:1–20.
  22. Kefayat A, Hosseini M, Ghahremani F, Jolfaie NA, Rafienia M. Biodegradable and biocompatible subcutaneous implants consisted of pH-sensitive mebendazole-loaded/folic acid-targeted chitosan nanoparticles for murine triple-negative breast cancer treatment. J Nanobiotechnology. 2022;20(1):169.
  23. Faid AH, Shouman SA, Badr YA, Sharaky M, Mostafa EM, Sliem MA. Gold nanoparticles loaded chitosan encapsulate 6-mercaptopurine as a novel nanocomposite for chemo-photothermal therapy on breast cancer. BMC Chem. 2022;16(1):94.
  24. Cao M, Gao Y, Qiu N, Shen Y, Shen P. Folic acid directly modified low molecular weight of polyethyleneimine for targeted pDNA delivery. J Drug Deliv Sci Technol. 2020;56:101522.
  25. Eslaminejad T, Nematollahi-Mahani SN, Sargazi ML, Ansari M, Mirzaie V. Evaluating the effects of curcumin nano-chitosan on miR-221 and miR-222 expression and Wnt/β-catenin pathways in MCF-7, MDA-MB-231 and SKBR3 cell lines. Diagn Pathol. 2024;19(1):35.
  26. Ali M, Mir S, Ajlouni A, Alvi SG, Bibi S. Applications Of Chitosan Based Bionanocomposites In Drug-Delivery And Anticancer Treatment-A Review. Eur Polym J. 2023;201:112576.